Beneficial Ownership Report · SCHEDULE 13G/A
Freenome, Inc.
FRNMNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Freenome, Inc.
- Company CIK
- 0002017526
- Street
- GENESIS MARINA, 3300 MARINA BLVD
- City
- BRISBANE
- State / country code
- CA
- Postal code
- 94005
Statement details
- Amendment number
- 2
- Security class
- Common Stock
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b) · Rule 13d-1(c)
Reporting person 1
- Name
- One Fin Capital Management LP
- Citizenship / organization
- DE
- Reporting person type
- IA · PN
- Group designation
- b
- Aggregate amount owned
- 1,208,742
- Percent of class
- 1.1
- Sole voting power
- 0
- Shared voting power
- 1,208,742
- Sole dispositive power
- 0
- Shared dispositive power
- 1,208,742
Reporting person 2
- Name
- One Fin Capital Master Fund LP
- Citizenship / organization
- E9
- Reporting person type
- PN
- Group designation
- b
- Aggregate amount owned
- 1,208,742
- Percent of class
- 1.1
- Sole voting power
- 0
- Shared voting power
- 1,208,742
- Sole dispositive power
- 0
- Shared dispositive power
- 1,208,742
Reporting person 3
- Name
- One Fin Capital GP LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- b
- Aggregate amount owned
- 1,208,742
- Percent of class
- 1.1
- Sole voting power
- 0
- Shared voting power
- 1,208,742
- Sole dispositive power
- 0
- Shared dispositive power
- 1,208,742
Reporting person 4
- Name
- David MacKnight
- Citizenship / organization
- X1
- Reporting person type
- IN · HC
- Group designation
- b
- Aggregate amount owned
- 1,208,742
- Percent of class
- 1.1
- Sole voting power
- 0
- Shared voting power
- 1,208,742
- Sole dispositive power
- 0
- Shared dispositive power
- 1,208,742
Item 1
Issuer
Freenome, Inc.
Principal executive office address
Genesis Marina, 3300 Marina Blvd., Brisbane, CA 94005
Item 2
Citizenship
See Item 4 of the cover sheet for each reporting person.
Filing person
One Fin Capital Management LP, a Delaware limited partnership ("One Fin") One Fin Capital Master Fund LP, a Cayman Islands limited partnership (the "Partnership") One Fin Capital GP LLC, a Delaware limited liability company (the "General Partner") David MacKnight One Fin and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. MacKnight is the control person of One Fin and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
Principal business or residence address
One Letterman Drive, Building C, Suite C3-400, San Francisco, CA 94129
Item 3
Not applicable indication
N
Type of filing person
IA · HC
Item 4
Percent of class
One Fin: 1.1% Partnership: 1.1% General Partner: 1.1% David MacKnight: 1.1%
Amount beneficially owned
One Fin: 1,208,742 Partnership: 1,208,742 General Partner: 1,208,742 David MacKnight: 1,208,742
Sole voting power
One Fin: 0 Partnership: 0 General Partner: 0 David MacKnight: 0
Shared voting power
One Fin: 1,208,742 Partnership: 1,208,742 General Partner: 1,208,742 David MacKnight: 1,208,742
Sole dispositive power
One Fin: 0 Partnership: 0 General Partner: 0 David MacKnight: 0
Shared dispositive power
One Fin: 1,208,742 Partnership: 1,208,742 General Partner: 1,208,742 David MacKnight: 1,208,742
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- One Fin Capital Management LP
- Signed
- /s/ MayKao Y. Manisone
- Title
- Chief Compliance Officer
- Date
- 11/16/2026
Signature 2
- Reporting person
- One Fin Capital Master Fund LP
- Signed
- /s/ MayKao Y. Manisone
- Title
- Chief Compliance Officer of the General Partner, One Fin Capital GP LLC
- Date
- 11/16/2026
Signature 3
- Reporting person
- One Fin Capital GP LLC
- Signed
- /s/ MayKao Y. Manisone
- Title
- Chief Compliance Officer
- Date
- 11/16/2026
Signature 4
- Reporting person
- David MacKnight
- Signed
- /s/ David MacKnight
- Title
- Reporting person
- Date
- 11/16/2026
Filed exhibits
- JOINT FILING AGREEMENT ↗ex99.htm
Company context
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of SimpleScreen™ CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals. For more information, visit www.freenome.com.
Current securities
Historical securities (1)
Recent company filings
- SCHEDULE 13G/A - filed by ADAR1 Capital Management, LLC regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Holocene Advisors, LP regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by RTW INVESTMENTS, LP regarding Freenome, Inc.Nov 16, 2026